RE:RE:RE:The reality "So why cant Gilles ever sell more product?"
The base business has grown at a double digit rate for a decade. Symrise has stated, "We see great value in this partnership and are very pleased to have secured this agreement, which will continue to pave the way for future developments that I believe will benefit both companies in creating value.”
CZO has invested its profits not in first-generation avenanthramide but in developing second-generation/third-generation concentrated products which can add greater value and target much larger markets:
"We also expect to work closely with some major key customers who are looking for second and third generation products to be included in some well-known brands. These high concentration products of both liquid and powder formulations of avenanthramides are produced from our proprietary enabling technologies." Annual Report
Gilles's has invested the profits from first-generation avenanthramide into a potent pharma-grade pill. The pill has been successfully developed, and a trial protocol approved by Health Canada through to potential indications of efficacy with the Montreal Heart Institute. Gilles has noted that the non-steroidal anti-inflammatory market is worth $60 billion. Disease areas like heart disease are substantial. A news release has also stated CZO has investigated its avenanthramide with newer-generation PGX carriers with very promising results. We've seen what newer generation PGX carriers have been able to achieve with CoQ10 vs. the gold standard. PGX could create great new opportunities leveraging CZO's leadership in aventhramide production.
CZO has also run a human clinical trial using a cookie in the exercise inflammation study. The human biomarkers hit validated the development of the pill. The pill study will use much higher dosing. Gilles believes the pill may even help prevent exercise inflammation.
Oat flour with higher concentration avenanthramide is also being scaled-up this year and has significant markets. Wound healing data has also recently been released opening new opportunities.
Gilles said he was attracted to CZO originally because of avenanthramide. He has turned the base business, first-generation avenanthramide into a profit engine with C$20 billion market cap Symrise, and the profit stream into a number of potential high-impact second-generation/third generation avenanthramide opportunities that could significantly increase CZO's leadership and IP.